Illumina plunges as talks falter

Investor's Business Daily

Shares of the genetics firm tumbled after Roche (OTCPK:RHHBY) said Illumina (ILMN) was "off the table" as a buyout target. Meanwhile, Illumina said it's agreed to buy Verinata Health, which makes tests to detect chromosomal abnormalities in fetuses, for $300 mil plus $100 mil in milestone payments. Over the weekend, Swiss newspaper SonntagsZeitung published an interview with Roche Chairman Franz Humer in which he said negotiations broke down over price. Illumina shares fell 7.1% to 50.90.

View Comments (0)